SREBF1 and fatty liver disease: Previous studies have reported that the selected major compounds, such as kaempferol and tanshinone IIA, inhibit the proliferation of HSCs [21], luteolin has hepatoprotective activity through the regulation of SREBP-1c phosphorylation and AMP-activated protein kinase [27], beta-sitosterol prevents hepatotoxicity [28], and hederagenin can attenuate non-alcoholic hepatic steatosis [29].